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Over the past 15 years, DNA vaccines have gone from a scientiﬁc curiosity to one of the most dynamic research ﬁeld and may oﬀer
new alternatives forthecontrol of parasitic diseases such as leishmaniasis and Chagas disease. We review heresomeof theadvances
and challenges for the development of DNA vaccines against these diseases. Many studies have validated the concept of using DNA
vaccines for both protection and therapy against these protozoan parasites in a variety of mouse models. The challenge now is to
translate what has been achieved in these models into veterinary or human vaccines of comparable eﬃcacy. Also, genome-mining
and new antigen discovery strategies may provide new tools for a more rational search of novel vaccine candidates.
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1. INTRODUCTION
In spite of the success of vaccines in public health, there are
still numerous pathogens, and in particular protozoan par-
asites such as Plasmodium falciparum, Trypanosoma sp., or
Leishmania sp. against which there are still no eﬀective vac-
cine. However, the discovery that the direct injection of plas-
mid DNA encoding foreign proteins could lead to endoge-
nous protein biosynthesis and a speciﬁc immune response
against it opened new perspectives in vaccine development.
Over 15 years later, DNA vaccines have gone from a scien-
tiﬁc curiosity to one of the most dynamic ﬁelds of research
and may oﬀer new alternatives for the control of infectious
diseases [1]. Indeed, the ﬁrst two DNA vaccines have been li-
cenced, in recent years, to protect horses from west nile virus
and salmons from infectious hematopoietic necrosis virus,
conﬁrming the usefulness of this biotechnology. We review
here some of the advances and challenges for the develop-
ment of DNA vaccines against two well-studied protozoan
parasites, Leishmania sp. and Trypanosoma cruzi. Both be-
long to the trypanosomatidae family and are ranked among
the three major protozoan parasites aﬀecting humans. Leish-
maniasis is a complex disease caused by at least 18 species
of parasites from the Leishmania genus and transmitted to
humans by hematophagous sandﬂies. With an estimated 12
million cases, it has a major public health impact in several
regions, and in particular in India, Sudan, and Brazil [2].
Clinical manifestations range fromself-healing cutaneous le-
sion to fatal visceral form, and this variety can be attributed
in part to the respective parasite species, and each presents
speciﬁc relationships with the host and diverse mechanisms
of pathogenesis [3, 4], which represents an additional diﬃ-
cultyforthedevelopmentoftreatmentsandvaccines.Onthe
other hand, T. cruzi is the agent of Chagas disease, which is
present from southern Argentina to the southern USA. An
estimated 16–18 million persons are infected in the Ameri-
cas and close to 100 million people are at risk of infection.
After a short benign acute phase (a few weeks) and a very
long (several years) asymtomatic phase, about 30–40% of in-
fectedpatientsdevelopchronicchagasiccardiomyopathyand
eventualy die of heart failure. Current chemotherapy relies
on nitrofurans (Nifurtimox), or nitroimidazoles (Benznida-
zole). However, the usefulness of these drugs is limited by
their reduced eﬃcacy (mostly during the early stages of the
infection), serious side eﬀects, and the emergence of drug-
resistant strains of parasites, and new treatments are slow to
develop [5].
2. WHY DNA VACCINES?
DNA vaccines induce a complete immune response against
the encoded antigen. The exact mechanisms involved in this
proccessarestillpoorlyunderstood,andparticularlythetype
of CD4+ and CD8+ eﬀector and memory cells activated, and2 Journal of Biomedicine and Biotechnology
some of these aspects have been reviewed in detail elsewhere
[1]. Apart from their immunogenicity and eﬃcacy that will
be discussed below, there are several features of DNA vac-
cines that make them very advantageous against tropical dis-
eases.First,theyareextremelysafeastheydonotcontainany
pathogenic organism that may revert in virulence. The ma-
jor concern of genomic integration of the plasmid DNA has
also extensively been studied in safety studies and found to
be rather unlikely [6]. Additional safety issues such as anti-
DNA antibodies or autoimmunity have also been addressed
in a growing number of preclinical and clinical studies [7],
which conﬁrmed the high safety of these vaccines. With re-
spect to manufacturing, storage, and distribution, they also
present major beneﬁts in that the production process is the
same for any DNA vaccine, which is not the case for other
types of biologicals and vaccines, for which a speciﬁc proto-
col has to be developed for each. This makes production easy
and costs will likely go down as this type of vaccines become
mainstream and future technological improvements are im-
plemented. Also, plasmid DNA is a very stable molecule,
specially compared to recombinant or live attenuated vac-
cines, which would greatly facilitate storage and distribution
of DNA vaccine in tropical settings with limited health in-
frastructure as the huge costs associated with the cold chain
may be oﬀset. Administration is also easy as simple IM or
ID injections can be suﬃcient, and multiple plasmids can
be combined for the elaboration of multivalent vaccines [1].
Overall, DNA vaccines may thus represent an ideally aﬀord-
ablealternativefordiseasecontrol,whichexplainsinpartthe
growinginterestintheirdevelopmentforthecontroloftrop-
ical parasitic diseases such as malaria, leishmaniasis, or Cha-
gas disease.
3. DNA VACCINES AGAINST LEISHMANIA
3.1. Correlatesforprotection
As mentioned above, leishmaniasis is caused by at least
18 species of parasites with diverse relationships with the
host and mechanisms of pathogenesis [3, 4]. Early stud-
ies of cross-protection between Leishmania species clearly
showed that it is a complex problem, with infection by one
species protecting or not from subsequent infection by an-
other species, depending on the species and the order of in-
fections.Mostvaccinestudieshavethusbeenfocusingonho-
mologous protection, although a single vaccine able to pro-
tect against all pathogenic species would be ideal.
The correlates for protection have been extensively stud-
ied in the case of L. major, and contributed considerably to
the development of the Th1/Th2 paradigm [8]. Thus, there
is a general agreement that a Th1-type immune response,
characterized by a high IFNγ and low IL-4 and IL-10 pro-
duction, leads to control of L. major infection, while a Th2-
type immune response does not [8]. Antibodies may have
an exacerbatory role [9], but may also contribute to T cell
responses [10, 11]. Both IFNγ producing CD4+and CD8+T
cells seem to contribute to protective immunity, and induc-
tion of NO production by macrophages is central to parasite
elimiation [12,13].Whileitwasassumedforalongtimethat
thisTh1/Th2paradigmwasappliedtoallLeishmaniaspecies,
it has become clear in recent years that each species has a
distinct relationship with the host, diﬀerent mechanisms of
pathogenesis, and possibly diﬀerent correlates for protection
[3, 4]. Nonetheless, IFNγ production seems to be a general
requirement, although not necessarily suﬃcient, for protec-
tion against most if not all Leishmania species.
3.2. SingleantigenDNAvaccines
The earliest DNA vaccine experiments against Leishmania
used L. major GP63 antigen, which has been extensively used
as a recombinant or peptide vaccine. Immunization with a
plasmid encoding GP63 was able to induce a Th1-type cy-
tokine proﬁle and a signiﬁcant reduction of lesion size after
challengeoftheimmunizedmicewithL.major [14–17].Sub-
sequent studies investigated DNA vaccines encoding a large
variety of Leishmania proteins (Table 1) and showed that
many diﬀe r e n tD N Av a c c i n e sw e r ea b l et oi n d u c eaT h 1i m -
mune response, and confer variable degrees of protection as
assessed by reduction in skin lesion size and/or parasite bur-
densinmousemodels.However,giventhelargevarietyinex-
perimental models and designs, it is diﬃcult to compare the
eﬀectiveness of the diﬀerent vaccines to induce a protective
immune response. Nonetheless, it is clear from studies com-
paring diﬀerent DNA vaccines that the nature of the antigen
encoded by the vaccine is a key parameter for eﬃcacy.
Also, a few studies provided interesting comparisons of
the same antigens administered as recombinant protein or
DNA vaccines and showed that the latter were overall more
eﬀective than their recombinant protein counterparts. In-
deed, DNA vaccines were able to induce a stronger Th1 bias
intheimmuneresponse,alonger-lastingimmunity,and/ora
better protection against disease progression [19, 31, 32, 35,
40, 44]. While most of these studies have used a rather artiﬁ-
cial infectious challenge based on the injection via nonnatu-
ralr out esofhighparasit ed oses,ane xperimentalsyst emcrit-
icizedbysomeauthors,thesuperioreﬃcacyofDNAvaccines
was also observed using a low-dose intradermal challenge in
the ear, which was proposed to more closely mimick natural
infection [45]. In these studies, both DNA and protein vacci-
nation were able to induce very similar level of short-term (2
weeks postvaccination) protection against infection with L.
major, but only DNA vaccine was able to induce long-term
(12 weeks postvaccination) protection [45].
TheseresultsthusconﬁrmedthestrongpotentialofDNA
vaccines against Leishmania, but also indicated that in most
cases only partial protection was achieved. Prime-boost im-
munization protocols have been tested with various anti-
gens to increase vaccine potency (Table 1). They are based
on priming the immune response with a DNA vaccine and
boosting with the corresponding recombinant vaccine based
on recombinant virus or protein (Table 1). In some studies,
such immunization protocol resulted in increased immuno-
genicity of the vaccines and better protection levels [26, 27],
but in others, DNA only remained the best formulation for
optimum eﬃcacy [32]. Nonetheless, a major drawback ofEric Dumonteil 3
Table 1: DNA vaccines tested against murine leishmaniasis.
Antigen Dose Challenge Immune response Protection Reference
GP63 2 ×100μgI M L. major Th1 +++ [14–17]
LACK 2 ×100μgI M L. major Th1, IFNγ +++ [18–21]
LACK 2 ×30μgI N L. amazonensis +++ [22]
LACK 2 ×100μgI M L. mexicana − [23]
LACK 2 ×100μgI Mo rS C L. chagasi Th1, IFNγ − [24]
LACK 2 ×100μgI Do rS C L. chagasi Th1 − [25]
LACK Prime/boost L. major Th1 +++ [26]
LACK Prime/boost L. major Th1 +++ [27]
LACK Prime/boost L. major Th1, IFNγ +++ [28]
LACK Prime/boost L. infantum IFNγ +++ [29]
TRYP Prime/boost L. major IFNγ +++ [30]
LiP0 2 ×100μgi m L. major Th1 ++ [31]
SP1 2 ×100μg SC or prime/boost L. major IFNγ ++ [32]
Histones mix: H2A, H2B,
H3, H4
3 ×200μgI M L. major Th1, IFNγ +++ [22]
LmSTI1,TSA 3 ×100μgI M L. major Th1 +++ [33]
LACK, LmSTI1, TSA 1 ×300μgS C L. major Th1 +++ [13]
CPb/CPa 2 ×100μgI M L. major Th1 +++ [34]
PSA-2 2 ×20–50μgI M L. major Th1 +++ [35]
LACK, PSA2, Gp63, LeIF,
p20 Ribosomal like protein
1 ×50μgI M L. major − to +++ [36]
Meta 1 3 ×100μgI M L. major Th2 − [37]
P4 3 ×100μg various sites L. amazonensis Th1 +++ [38]
CPb, GP63, GP46 2 ×100μgI M L. mexicana + to +++ [23, 39]
NH36 2 ×100μgI M L. domovani +++ [40]
L. mexicana ++
NH36, GP63 2 ×20μgI M L. mexicana IFNγ +++ [41]
CPa/CPb Prime/Boost L. infantum Th1, IFNγ +++ [42]
ORFF 3 ×100μgI M L. donovani +++ [43]
IM: intramuscular; IN: intranasal; SC: subcutaneous; −: no protection; +: little protection; ++: fair protection; +++: very good protection.
such vaccine formulation remains its complexity, which may
limit their practical use.
3.3. MultipleantigenDNAvaccines
An alternative way to broaden vaccine immunogenicity and
increase its eﬃcacy has been to use combination of plas-
mids encoding various antigens. For examples, cysteine pro-
teinase (CP) a and b DNA vaccines are not protective when
used individually, but immunization with a combination of
both plasmids induces long-term protective immunity [34].
Alternatively, gene fusion has also been successively used to
achieve expression of an antigenic fusion protein from a sin-
gle plasmid construct [33]. Overall, expression of several
antigens mostly resulted in increased eﬃcacy, but this also
depended on the antigen combination [13, 22, 23, 41, 45].
Most authors thus argue that a successful Leishmania vaccine
is likely to be based on multiple antigens.
3.4. Antigendiscovery
Immunizationwithlargenumberofplasmidsisalsothebasis
for expression library immunization, a powerful but labor-
intensive strategy for vaccine discovery [46], which has been
used with Leishmania. Immunization of mice with L. ma-
jor genomic expression library fractions was able to induce
signiﬁcant protection, but these authors did not pursue li-
brary fractionation further [47]. In another study, the iden-
tiﬁcation of protective library subsets from an L. donovani
amastigote cDNA library and their successive fractionation
into smaller protective libraries lead to the identiﬁcation of
novelprotectiveantigens[48].Interestingly,mostoftheanti-
gens identiﬁed would not have been predicted to be good4 Journal of Biomedicine and Biotechnology
vaccine candidates. Indeed, they were not surface or secreted
proteins, neither stage-speciﬁc, but were intracellular and
some very conserved such as histones, or ribosomal proteins
[48]. Vaccine discovery is also the next logical step following
the recent completion of the L. major genome sequencing
[49]. In one approach, the random screening of 100 genes
upregulated in amastigotes tested as DNA vaccine allowed
the identiﬁcation of 14 novel protective and 7 exacerbating
antigens [50, 51]. Again, function and cellular localization
would have been poor predictors of the protective eﬃcacy
of these antigens, as most were not predicted to be localized
onthesurface,butsharedsimilaritywithribosomalproteins,
cytoskeleton, or metabolic enzymes [51]. It is thus becoming
increasingly clear that there is little rationale to limit Leish-
mania vaccine discovery searches to surface or secreted anti-
gens. Rather, new criteria need to be considered for the ratio-
nal identiﬁcation of vaccine candidates as strategies based on
such random screening cannot be applied to large genomes
such as that of Leishmania, with over 8000 annotated genes.
3.5. Therapeuticvaccines
An additional advantage of DNA vaccines is their potential
as therapeutic vaccines, aimed at reinforcing or redirecting
the immune response of an infected host to control disease
progression [58]. The major advantage of this strategy in ad-
dition to its eﬃcacy is that it relies on short treatment regi-
mens,anditisthusanattractivealternativetochemotherapy,
particularlyinthecaseofLeishmaniawithsofewchemother-
apeuticoptions. Thus,administration ofaslittleastwodoses
ofaDNAvaccineencodingPSA-2cancontrolanongoingin-
fection with L. major in mice [59]. The therapeutic eﬀect is
due to a shift of the immune response towards a Th1 im-
mune response [59]. Similarly, a DNA vaccine encoding L.
donovani nucleoside hydrolase NH36 has therapeutic activ-
ity against murine visceral leishmaniasis caused by L. chagasi
[60]. The simplicity of such treatment makes them very ad-
vantageous compared to chemotherapy. In addition, the fact
that the same DNA vaccine can be eﬀective for both the pro-
phylaxis [40] and the therapy of Leishmania infection is thus
very promising as this would provide a versatile tool for the
control of this parasite.
3.6. Cross-protectionagainstmultiple
Leishmaniaspecies
As mentioned above, an added challenge to Leishmania vac-
cine development is the large number of species, as well as
the variability within species. Indeed, studies on the poly-
morphism of leading antigens such as GP63 quickly revealed
that it was a very polymorphic [61, 62]. Such polymorphism
has important implication for vaccine development as it may
limittheireﬃcacyagainstvariantstrainsofparasitesornovel
escape mutants, and thus restrict vaccine protection to a sin-
gle species [63, 64]. Antigen polymorphism between mul-
tiple strains and species is thus becoming a major issue in
many vaccine development studies [65, 66]. In the case of
Leishmania, few DNA vaccines have been tested against mul-
tiple species. LACK antigen, initially identiﬁed in L. major,
and found to be very conserved between Leishmania species,
can protect mice against L. major [20]a n dL. amazonensis
[67], but not against L. mexicana [23], L. donovani [25], or
L. chagasi [24]. On the other hand, L. amazonensis nucle-
ase protein P4 can protect against both L. amazonensis and
L. major, but cross-protection requires a diﬀerent formula-
tion (IL-12 or HSP70 as adjuvant, resp.) [38]. In other stud-
ies, antigens from one species were used to induce protec-
tion against another species [31], but the extent of cross-
protection against various species was not investigated. More
recently,asingleformulationofL.donovaniNH36DNAvac-
cine was found to induce a very good protection against both
L. chagasi and L. mexicana, suggesting that this DNA vac-
cine may be able to provide broad protection against various
Leishmania species [40]. Importantly, no DNA vaccine has
y e tb e e nt e s t e da g a i n s tL. braziliensis, in spite of this species
beingresponsibleofmostcasesofcutaneousleishmaniasisin
South America.
3.7. Non-Leishmaniaantigensasvaccines
While all the above DNA vaccines were based on Leishmania
antigens, an alternative approach has used antigens derived
from sand-ﬂy saliva. Indeed, it has been shown that sand-ﬂy
saliva can exacerbate Leishmania infection [68, 69], and pre-
exposure of mice to saliva components may be suﬃcient to
induce protection against infection [70]. Thus, a number of
salivary antigens have been tested as vaccines against Leish-
mania.Maxadilanisapotentvasodilatorfromsand-ﬂysaliva
and was found to be responsible of most of the exacerbatory
eﬀects of whole saliva on Leishmania infection [71]. Immu-
nization with this antigen (as a recombinant vaccine) pro-
tected mice against L. major infection [71]. Other salivary
components, such as Phlebotomus papatasi SP15, have been
tested as DNA vaccines and found to protect mice against
L. major and while the vaccine induced both humoral and
DTH responses, protection seemed to be mostly accounted
for by the latter, as B-cell deﬁcient mice remain protected
[72].Thus,characterizationofsand-ﬂysalivaryproteins may
lead to the identiﬁcation of new vaccine candidates [73, 74].
However, as for Leishmania antigens, salivary protein poly-
morphismremainsanimportantissueandmaylimittheuse-
fulness of such antigens as vaccine candidates [75, 76].
3.8. DNAvaccinesagainstnonmurineleishmaniasis
Based on the success of many of these DNA vaccine studies
in mice, a few vaccine candidates have been tested in addi-
tional animal models, possibly more relevants for the devel-
opment of a veterinary or human vaccine (Table 2). PFR-2
and KMP11 antigens were tested as DNA vaccines in ham-
sters, a highly susceptible animal model. PFR-2 was tested as
protein, DNA, or DNA-protein immunization, and protec-
tion levels against L. mexicana varied greatly depending on
vaccine formulation, route of immunization, and sex of the
animals [52]. Also, contrary to mouse studies, protein vacci-
nation seemed more protective than DNA only vaccination.Eric Dumonteil 5
Table 2: Preclinical studies Leishmania DNA vaccines in nonmurine models.
Antigen Dose Challenge Host Immune response Protection Reference
PFR-2 Variable L. mexicana Hamster − to +++ [52]
L. panamensis
KMP11 2 ×100μgI M L. donovani Hamster Th1-Th2 +++ [53]
PapLe22 1 ×100μgI M L. infantum Hamster +++ [54]
LACK 2 × 100μg IM or Prime/boost L. infantum Dog Th1/Th2 Th1 + to +++ [55]
10 antigens mix 2 ×500μgI M L. donovani Dog Th1 [56]
CPa/b Prime/boost L. infantum Dog IFNγ +++ [57]
−: no protection; +: little protection; ++: fair protection; +++: very good protection.
However, as in mouse studies, heterologous prime-boost
vaccination with DNA and protein seemed better than DNA
only [52]. Another DNA vaccine encoding PapLe22 was
found to be immunogenic in hamsters and decreased par-
asitemia after infection with L. infantum, but further assess-
ment of disease was not performed [54]. Immunization with
KPM11 DNA induced a mixed Th1/Th2 response, but was
able to protect hamsters against visceral leishmaniasis caused
by L. donovani [53]. In dogs, while several protein vaccines
have been tested and a puriﬁed protein vaccine has now been
licenced for veterinary use [77], very few DNA vaccine stud-
ies have been performed. A heterologous prime-boost strat-
egy using CPa and CPb DNA and protein was reported as
immunogenic and protective [57], but the study was of lim-
ited power given the reduced number of animals. In another
study, dogswereimmunized witha mixtureofDNAvaccines
encoding 10 diﬀerent antigens previously tested in mouse
models,andthisimmunizationinducedaverygoodimmune
response, with a high production of IFNγ [56]. However,
evaluation of protection was limited to an acute in vitro assay
[56] and further studies will be required to assess the poten-
tial of this vaccine in dogs. In spite of their limitations, these
studies clearly showed that several DNA vaccines can induce
a potent immune response in nonmurine animal models,
and it is likely that a good level of protection can be achieved
in these as well, provided the correct antigens and vaccine
formulation are used.
4. DNA VACCINES AGAINST TRYPANOSOMACRUZI
4.1. Correlatesforprotection
Vaccine development against Chagas disease has been dra-
matically limited because of extensive debate on the mecha-
nismsinvolvedinthispathology[78,79].Indeed,somestud-
iessuggestedthattissuedamagewasassociatedwiththepres-
enceandreplicationofintracellularamastigotes,whileothers
proposed that autoimmunity induced by parasite antigens
mimicking host proteins was responsible for it. It was thus
uncleariftheimmuneresponseneededtobeinhibited,tore-
duce autoimmunity, or stimulated, to eliminate the parasite.
It is now accepted that the presence of parasites in cardiac
tissue is necessary to initiate and maintain the inﬂammatory
response, and that therapeutic treatments or vaccines aimed
at eliminating T. cruzi would limit or prevent the progression
towardschronicchagasiccardiomyopathy[80,81].Ther eisa
growing consensus that protection against T. cruzi relies on a
Th1immuneresponseandtheactivationofcytotoxicCD8+T
cells [82–85].
4.2. SingleantigenDNAvaccines
The ﬁrst DNA vaccines to be tested against T. cruzi encoded
an antigen from the well characterized trans-sialidase fam-
ily of proteins. There are over 1400 members in this fam-
ily, making it one of the largest protein families of the par-
asite, and they are very abundant surface proteins. Several
studies have used diﬀerent members of this family, such as
TS or TSA-1 (Table 3)[ 84, 86–88]. Immunization with TS
was found to induce signiﬁcant antibody titers able to in-
hibittrans-sialidaseenzymeactivity,astrongDTH,andlym-
phoproliferative response [86]. This immune response was
protective as determined by an increase in survival and a de-
crease in parasitemia. Immunization with TSA-1 DNA was
found to induce a speciﬁc CTL response which also lead to a
lowerparasitemiaandincreasedsurvivalinbothBALB/cand
C57BL/6 mice [88].
AsinLeishmaniavaccinestudies,afewauthorsaddressed
the question of comparing protein and DNA vaccines encod-
ing the same antigen [90, 98]. In A/Sn mice, immunization
withrecombinantTSinducedahigherantibodytiterthanTS
DNA, but a comparable decrease in parasitemia. However,
the DNA vaccine was unable to increase survival, which the
author attributed to the strain of the mice used, since this
DNA vaccine was protective in BALB/c mice [90]. On the
other hand, immunization with recombinant CRP or CRP
DNA induced a comparable Th1 immune response, but only
the DNA vaccine was protective against infection [98].
AnumberofotherstudiesshowedthatDNAvaccinesen-
coding various antigens could induce signiﬁcant protection
against T. cruzi infection, as evidenced by decreased para-
sitemia and improved survival of vaccinated mice (Table 3).
In addition, a few studies also presented evidence of a re-
duction in cardiac tissue damage and inﬂammation at the
histopathologic level [87, 97]. Furthermore, T cell analysis
conﬁrmed that protection relied on CD8+T cells[84, 91]a n d
recent studies showed that these cells were very rapidly acti-
vated following infection of mice immunized with DNA vac-
cines [101]. DNA vaccines based on deﬁned T cell epitopes
from TS antigen have also been tested and it was found that6 Journal of Biomedicine and Biotechnology
Table 3: DNA vaccines tested against Trypanosoma cruzi.
Antigen Type of antigen Dose Mouse strain Immune response Protection Reference
TS 154 TS family BALB/c Th1, CTL +++ [84, 89, 90]
A/Sn −
TSA-1 TS family 2 ×100μgI M C57BL/6
BALB/c
CTL +++ [87, 91]
ASP-1 TS family 2 ×100μgI M C57BL/6 CTL +++ [87]
ASP-2 TS family 2 ×100μgI M C57BL/6 CTL +++ [87]
Tc13 TS family 5 ×50μgI M BALB/c − [92]
ASP-clone9 TS family 4 ×100μgI M BALB/c IFNγ +++ [93]
TSSA TS family 2 to 4 ×100μgI M
BALB/c,
C57BL/6
C3H/Hej
CTL − to +++ [94, 95]
TS (7 members mix) TS family 2 ×25μgI M C57BL/6 +++ [96]
ASP-clone9, TS TS family 4 ×200μgI M BALB/c IFNγ +++ [97]
CRP 2 ×100μgI M BALB/c +++ [98]
cruzipain BALB/c CTL [99]
DHOD 2 to 4 ×100μgI M
BALB/c,
C57BL/6
C3H/Hej
− [94]
LYT1 2 ×25μg C57BL/6 IFNγ, CTL +++ [96]
FCaBP/Tc24 2 ×25μg C57BL/6 IFNγ,C T L − [96]
Tcβ32 ×25μg C57BL/6 IFNγ, CTL ++ [96]
Mucin (6 members) 2 ×25μg C57BL/6 − [96]
KMP11 4 doses IM BALB/c CTL − to ++ [100]
IM: intramuscular; CTL: cytolytic activity; −: no protection; +: little protection; ++: fair protection; +++: very good protection.
both CD4+and CD8+T cell epitopes were necessary and suf-
ﬁcient to induce a protective immune response [102].
Taken together, these data clearly demonstrated that vac-
cination did not result in increased pathology, as initially
feared, but allowed at least partial control of disease progres-
sion, thus conﬁrming the central role of parasite persistence
for Chagas disease pathogenesis and opening the way to fur-
ther assessment of DNA vaccines against T. cruzi.H o w ev e r ,i t
has to be noted that many of the antigens tested belonged to
the trans-sialidase family of protein, so that there is still little
diversity in terms of the antigens tested as vaccines against T.
cruzi (Table 3).
4.3. StrategiesforpotentiatingT.cruziDNAvaccines
Because protection induced by single antigen DNA vaccine
remained partial, a number of studies have evaluated strate-
gies to increase vaccine eﬃcacy. These include the use of
cytokine/chemokineencodingplasmidstopotentiatetheim-
mune response induced by the vaccine, and two of the most
studied molecules have been IL-12 and GM-CSF, which both
were generally able to potentiate protection (Table 2). Al-
ternatively, mixtures of plasmids encoding distinct antigens
were used for immunization, and as mentioned above for
Leishmania vaccines. For example, immunization of mice
with plasmids encoding TS and ASP-2 proteins resulted in
a speciﬁc immune response against both antigens and an in-
creased protection against infection [97]. On the other hand,
an immunization with a mixture of DNA vaccines encod-
ing up to 6 proteins from the mucin family resulted poorly
protective, while a mixture of up to 7 proteins from the TS
family was protective, but not as much as a single antigen
vaccine encoding the TS-like antigen ASP-2 [96]. Similarly, a
mixtureofDNAvaccinesencodingASP-1,ASP-2,andTSA-1
hadasimilarprotectiveactivityasTSA-1alone[87].Thelack
of eﬃcacy of these multivalent vaccines may be attributed to
the presence of shared or immunodominant epitopes since
they have signiﬁcant sequence similarity that may not have
resulted in a broader immune reponse.
Heterologous prime-boost approach has also been eval-
uated and immunization with some combinations of DNA
and recombinant TS was found to enhance Th1 immune
response, but protection was not signiﬁcantly diﬀerent from
that obtained with DNA alone [103]. Taken together, these
studies suggest that additional strategies need to be investi-
gated to potentiate DNA vaccine eﬃcacy against T. cruzi.
4.4. TherapeuticDNAvaccines
Therapeutic administration of DNA vaccines to control an
ongoing infection with T. cruzi may represent an additionalEric Dumonteil 7
alternative for Chagas disease control. The concept was
demonstrated in mice acutely or chronically infected, and
in both cases the administration of only two doses of DNA
vaccine encoding TSA-1 or Tc24 antigens was suﬃcient to
limitdisease progression, astreatedmicepresentedincreased
survival and reduced cardiac tissue damage, as assessed by
histopathologicanalysis[104].Acomparativestudyofdiﬀer-
ent DNA vaccines identiﬁed Tc52 antigen as another thera-
peuticvaccinecandidate,whileDNA vaccinesencoding anti-
gens from the TS family previously found to be protective
had no signiﬁacnt therapeutic eﬀect [105]. It was found that
therapeutic vaccination rapidly induced spleen cell prolif-
eration, including IFNγ-producing CD4+ and CD8+T cells,
while the eﬀects on cardiac tissue inﬂammation and para-
siteburdentakelongertobedetectable[106].Importantly,in
all these studies, therapeutic vaccination of T. cruzi infected
mice did not result in an increased inﬂammatory reaction in
the heart, conﬁrming that it is safe to stimulate the immune
response of T. cruzi infected mice and that attacking the par-
asite can lead to a reduction of pathology. These studies thus
openveryattractiveperspectivesforthecontrolofT.cruziin-
fection, and further studies on the eﬃcacy of DNA vaccines
encoding other antigens and on the immune mechanisms
underlying their therapeutic eﬀect should provide clues for
the optimization of this strategy.
4.5. Antigendiscovery
As for any vaccine, the nature of the antigen used remains
a key factor for vaccine eﬃcacy, and there is still little va-
riety in terms of antigens evaluated as DNA vaccine candi-
dates against T. cruzi.T h u s ,an u m b e ro fs t u d i e sh a v ea i m e d
at identifying novel antigens through various strategies. The
most classical approach has been the screening of cDNA
libraries using antibodies and screening an amastigote li-
brary allowed the identiﬁcation of a novel antigen Tcβ3, and
two previously characterized ones, LYT1 and FcaBP/Tc24
[96]. DNA vaccines encoding these antigens induced vari-
able levels of protection, the best one being LYT [96]. Alter-
natively, expression-library immunization, described above
for Leishmania, was also tested with T. cruzi,a n df o u n dt o
be immunogenic, but there was no attempt at fractionating
the library or identifying protective antigens [107]. A likely
reason is that such strategy may be too labor-intensive for
large genomes/libraries, and its usefulness may be limited to
pathogens with small genomes. The availability of T. cruzi
genome sequence also opens new possibilities for antigen
discovery. In one of the ﬁrst studies using such resource, a
combination of bioinformatics analysis were used to identify
GPI-anchored or secreted proteins, and most of the identi-
ﬁed clones were immunogenic as DNA vaccines [108]. Fur-
ther studies may conﬁrm the usefulness of these new vac-
cinestoprotectagainstT.cruziinfection.Nonetheless,asdis-
cussed above for Leishmania, the rationale for limiting anti-
gen searches to surface proteins may not be totally relevant,
and additional strategies should also be used to include un-
biaised genome-wide surveys for antigen discovery.
5. FUTURE DIRECTIONS
As detailed in this review, there have been considerable ad-
vancesinDNAvaccinesagainstLeishmaniaandT.cruziinre-
cent years. Taken together, these studies clearly validated the
concept of using DNA vaccines for both protection and ther-
apy against these protozoan parasites in a variety of mouse
models. While sterile immunity seems to be an irrealistic
goal for either Leishmania or T. cruzi, a reduction in dis-
ease severity and in the development of the pathology seems
clearly within the reach of DNA vaccines. Nonetheless, the
relevance of such mouse models for the development of vet-
erinary or human vaccines against these parasites has been
challenged by some authors. The few DNA vaccine studies
in nonmurine models of leishmaniasis suggest that some ex-
trapolationmaybefeasible,butcertainlynotcompletely.Ad-
ditional advanced preclinical studies of DNA vaccine candi-
dates in nonmurine animal models such as rats, hamsters,
dogs, or monkeys are thus warranted in the next few years, to
further explore the immunology and eﬃcacy of DNA vac-
cines against these parasites. As already observed in such
studies for other pathogens, this will lead to the challenge of
achieving in these species an immunogenicity of comparable
level and protective eﬃcacy as that obtained in murine mod-
els. However, advances in adjuvants, DNA vaccine formula-
tion, and delivery systems are likely to contribute to such re-
sults [1, 109].
Another major issue is that of antigen discovery, and
while a number of DNA vacines tested so far against Leish-
mania or T. cruzi have shown promise, we are still unsure if
these are the best possible antigens, particularly since these
parasites have relatively large genomes, and only a limited
variety of antigens have been tested. The availability of the
genome sequences of these parasites will without doubt be
a key resource for genome-wide screenings for new protec-
tive antigens. A key lesson from the initial studies reviewed
here[48,51,108],togetherwithothersimilarantigendiscov-
ery studies, seems to be that cellular localization and protein
function are poor predictors of the antigenicity and protec-
tive eﬃcacy of a protein. Alternative criteria should thus be
used so that potent vaccine candidates are not missed, and
theimportantdevelopmentofgenome-miningandbioinfor-
matic tools is providing new tools for a more rational search
of vaccine candidates [110].
To conclude, those DNA vaccines represent a promising
approach for the control of Leishmania sp. and T. cruzi,a n d
such vaccines would have a major impact in developing en-
demic countries. Thus the question does not seem to be if
DNA vaccines can control these parasites, since many studies
have clearly showed that this is the case, but how to translate
what has been achieved in mouse models into veterinary or
human vaccines of comparable eﬃcacy.
ACKNOWLEDGMENT
This work was funded by Grant SEP-2004-C01-47122 from
the Consejo Nacional de Ciencia y Tecnolog´ ıa (CONACYT).8 Journal of Biomedicine and Biotechnology
REFERENCES
[ 1 ]M .A .L i u ,B .W a h r e n ,a n dG .B .K .H e d e s t a m ,“ D N Av a c -
cines: recent developments and future possibilities,” Human
Gene Therapy, vol. 17, no. 11, pp. 1051–1061, 2006.
[ 2 ] H .W .M u r r a y ,J .D .B e r m a n ,C .R .D a v i e s ,a n dN .G .S a r a v i a ,
“Advances in leishmaniasis,” The Lancet, vol. 366, no. 9496,
pp. 1561–1577, 2005.
[3] J. Alexander and K. Bryson, “T helper (h)1/Th2 and Leish-
mania: paradox rather than paradigm,” Immunology Letters,
vol. 99, no. 1, pp. 17–23, 2005.
[ 4 ]D .M c M a h o n - P r a t ta n dJ .A l e x a n d e r ,“ D o e st h eLeishmania
major paradigmofpathogenesisandprotectionholdforNew
World cutaneous leishmaniases or the visceral disease?” Im-
munological Reviews, vol. 201, no. 1, pp. 206–224, 2004.
[5] J. A. Castro, M. M. de Mecca, and L. C. Bartel, “Toxic side
eﬀects of drugs used to treat Chagas’ disease (American try-
panosomiasis),”HumanandExperimentalToxicology,vol.25,
no. 8, pp. 471–479, 2006.
[6] R. L. Sheets, J. Stein, T. S. Manetz, et al., “Biodistribution of
DNA plasmid vaccines against HIV-1, Ebola, Severe Acute
Respiratory Syndrome, or West Nile virus is similar, without
integration, despite diﬀering plasmid backbones or gene in-
serts,”Toxicological Sciences,vol.91,no.2,pp.610–619,2006.
[7] R. L. Sheets, J. Stein, T. S. Manetz, et al., “Toxicological safety
evaluation of DNA plasmid vaccines against HIV-1, Ebola,
Severe Acute Respiratory Syndrome, or West Nile virus is
similar despite diﬀering plasmid backbones or gene-inserts,”
Toxicological Sciences, vol. 91, no. 2, pp. 620–630, 2006.
[8] J. Louis, H. Himmelrich, C. Parra-Lopez, F. Tacchini-Cottier,
and P. Launois, “Regulation of protective immunity against
Leishmania major in mice,” Current Opinion in Immunology,
vol. 10, no. 4, pp. 459–464, 1998.
[ 9 ]S .A .M i l e s ,S .M .C o n r a d ,R .G .A l v e s ,S .M .B .J e r o n i m o ,
and D. M. Mosser, “A role for IgG immune complexes during
infection with the intracellular pathogen Leishmania,” The
Journal of Experimental Medicine, vol. 201, no. 5, pp. 747–
754, 2005.
[10] S. St¨ ager, J. Alexander, A. C. Kirby, et al., “Natural antibod-
ies and complement are endogenous adjuvants for vaccine-
induced CD8+ T-cell responses,” Nature Medicine, vol. 9,
no. 10, pp. 1287–1292, 2003.
[11] F. Woelbing, S. L. Kostka, K. Moelle, et al., “Uptake of Leish-
mania major by dendritic cells is mediated by Fcγ receptors
and facilitates acquisition of protective immunity,” The Jour-
nal of Experimental Medicine, vol. 203, no. 1, pp. 177–188,
2006.
[12] C. Bogdan and M. R¨ ollinghoﬀ, “The immune response to
Leishmania:mechanismsofparasitecontrolandevasion,”In-
ternational Journal for Parasitology, vol. 28, no. 1, pp. 121–
134, 1998.
[13] S. M´ endez, Y. Belkaid, R. A. Seder, and D. Sacks, “Optimiza-
tion of DNA vaccination against cutaneous leishmaniasis,”
Vaccine, vol. 20, no. 31-32, pp. 3702–3708, 2002.
[14] P. S. Walker, “American Academy of Dermatology 1997
Awards for Young Investigators in Dermatology. Direct tar-
geting of skin with DNA vaccines for genetic immunization
against Leishmania in a murine model,” J o u r n a lo ft h eA m e r -
ican Academy of Dermatology, vol. 37, no. 5, part 1, pp. 776–
777, 1997.
[15] P. S. Walker, T. Scharton-Kersten, E. D. Rowton, et al., “Ge-
netic immunization with glycoprotein 63 cDNA results in
a helper T cell type 1 immune response and protection in
a murine model of leishmaniasis,” Human Gene Therapy,
vol. 9, no. 13, pp. 1899–1907, 1998.
[16] D. Xu and F. Y. Liew, “Genetic vaccination against leishmani-
asis,” Vaccine, vol. 12, no. 16, pp. 1534–1536, 1994.
[17] D. Xu and F. Y. Liew, “Protection against leishmaniasis by in-
jection of DNA encoding a major surface glycoprotein, gp63,
of L. major,” Immunology, vol. 84, no. 2, pp. 173–176, 1995.
[ 1 8 ] S .G u r u n a t h a n ,D .L .S a c k s ,D .R .B r o w n ,e ta l . ,“ V a c c i n a t i o n
with DNA encoding the immunodominant LACK parasite
antigen confers protective immunity to mice infected with
Leishmania major,” The Journal of Experimental Medicine,
vol. 186, no. 7, pp. 1137–1147, 1997.
[19] S. Gurunathan, C. Prussin, D. L. Sacks, and R. A. Seder,
“Vaccine requirements for sustained cellular immunity to
an intracellular parasitic infection,” Nature Medicine, vol. 4,
no. 12, pp. 1409–1415, 1998.
[20] S. Gurunathan, L. Stobie, C. Prussin, et al., “Requirements
forthemaintenanceofTh1immunityinvivofollowingDNA
vaccination: a potential immunoregulatory role for CD8+ T
cells,” The Journal of Immunology, vol. 165, no. 2, pp. 915–
924, 2000.
[21] L. Stobie, S. Gurunathan, C. Prussin, et al., “The role of anti-
gen and IL-12 in sustaining Th1 memory cells in vivo: IL-12
is required to maintain memory/eﬀector Th1 cells suﬃcient
to mediate protection to an infectious parasite challenge,”
Proceedings of the National Academy of Sciences of the United
States of America, vol. 97, no. 15, pp. 8427–8432, 2000.
[22] S. Iborra, M. Soto, J. Carri´ on, C. Alonso, and J. M. Requena,
“Vaccination with a plasmid DNA cocktail encoding the nu-
cleosomal histones of Leishmania confers protection against
murine cutaneous leishmaniosis,” Vaccine, vol. 22, no. 29-30,
pp. 3865–3876, 2004.
[23] E. Dumonteil, M. J. Ramirez-Sierra, J. Escobedo-Ortegonr,
andM.R.Garc´ ıa-Miss,“DNAvaccinesinducepartialprotec-
tion against Leishmania mexicana,” Vaccine, vol. 21, no. 17-
18, pp. 2161–2168, 2003.
[24] E. A. Marques-da-Silva, E. A. F. Coelho, D. C. O. Gomes,
et al., “Intramuscular immunization with p36(LACK) DNA
vaccine induces IFN-γ production but does not protect
BALB/c mice against Leishmania chagasi intravenous chal-
lenge,” Parasitology Research, vol. 98, no. 1, pp. 67–74, 2005.
[25] P. C. Melby, J. Yang, W. Zhao, L. E. Perez, and J. Cheng,
“Leishmaniadonovanip36(LACK)DNAvaccineishighlyim-
munogenic but not protective against experimental visceral
leishmaniasis,” Infection and Immunity,v o l .6 9 ,n o .8 ,p p .
4719–4725, 2001.
[26] R. M. Gonzalo, G. del Real, J. R. Rodriguez, et al., “A heterol-
ogous prime-boost regime using DNA and recombinant vac-
cinia virus expressing the Leishmania infantum P36/LACK
antigen protects BALB/c mice from cutaneous leishmania-
sis,” Vaccine, vol. 20, no. 7-8, pp. 1226–1231, 2002.
[27] E. Tapia, E. P´ erez-Jim´ enez, L. L´ opez-Fuertes, R. Gonzalo,
M. M. Gherardi, and M. Esteban, “The combination of
DNA vectors expressing IL-12 + IL-18 elicits high protec-
tive immune response against cutaneous leishmaniasis after
priming with DNA-p36/LACK and the cytokines, followed
by a booster with a vaccinia virus recombinant expressing
p36/LACK,” Microbes and Infection, vol. 5, no. 2, pp. 73–84,
2003.
[28] E. P´ erez-Jim´ enez, G. Kochan, M. M. Gherardi, and M. Es-
teban, “MVA-LACK as a safe and eﬃcient vector for vacci-
nation against leishmaniasis,” Microbes and Infection, vol. 8,
no. 3, pp. 810–822, 2006.Eric Dumonteil 9
[29] B. Dondji, E. P´ erez-Jimenez, K. Goldsmith-Pestana, M. Es-
teban, and D. McMahon-Pratt, “Heterologous prime-boost
vaccination with the LACK antigen protects against murine
visceral leishmaniasis,” Infection and Immunity,v ol.73,no .8,
pp. 5286–5289, 2005.
[ 3 0 ]C .B .S t o b e r ,U .G .L a n g e ,M .T .M .R o b e r t s ,A .A l c a m i ,a n d
J. M. Blackwell, “Heterologous priming-boosting with DNA
and modiﬁed vaccinia virus Ankara expressing tryparedoxin
peroxidase promotes long-term memory against Leishmania
major in susceptible BALB/c mice,” Infection and Immunity,
vol. 75, no. 2, pp. 852–860, 2007.
[31] S. Iborra, M. Soto, J. Carri´ on, et al., “The Leishmania infan-
tum acidic ribosomal protein P0 administered as a DNA vac-
cine confers protective immunity to Leishmania major infec-
tioninBALB/cmice,”Infection and Immunity,vol.71,no.11,
pp. 6562–6572, 2003.
[32] S. Rafati, F. Ghaemimanesh, and F. Zahedifard, “Comparison
of potential protection induced by three vaccination strate-
gies (DNA/DNA, Protein/Protein and DNA/Protein) against
Leishmania major infection using Signal Peptidase type I in
BALB/c mice,” Vaccine, vol. 24, no. 16, pp. 3290–3297, 2006.
[33] A. Campos-Neto, J. R. Webb, K. Greeson, R. N. Coler, Y.
A.W. Skeiky, and S. G. Reed, “Vaccination with plasmid DNA
encoding TSA/LmSTI1 leishmanial fusion proteins confers
protection against Leishmania major infection in suscepti-
ble BALB/c mice,” Infection and Immunity,v o l .7 0 ,n o .6 ,p p .
2828–2836, 2002.
[ 3 4 ]S .R a f a t i ,A . - H .S a l m a n i a n ,T .T a h e r i ,M .V a f a ,a n dN .
Fasel, “A protective cocktail vaccine against murine cuta-
neous leishmaniasis with DNA encoding cysteine proteinases
of Leishmania major,” Vaccine, vol. 19, no. 25-26, pp. 3369–
3375, 2001.
[35] A. Sj¨ olander, T. M. Baldwin, J. M. Curtis, and E. Handman,
“InductionofaTh1immuneresponseandsimultaneouslack
of activation of a Th2 response are required for generation
of immunity to leishmaniasis,” The Journal of Immunology,
vol. 160, no. 8, pp. 3949–3957, 1998.
[36] S. B. H. Ahmed, C. Bahloul, C. Robbana, S. Askri, and K.
Dellagi, “A comparative evaluation of diﬀerent DNA vaccine
candidates against experimental murine leishmaniasis due to
L. major,” Vaccine, vol. 22, no. 13-14, pp. 1631–1639, 2004.
[37] C.H.C.Serezani,A.R.Franco,M.Wajc,etal.,“Evaluationof
the murine immune response to Leishmania meta 1 antigen
delivered as recombinant protein or DNA vaccine,” Vaccine,
vol. 20, no. 31-32, pp. 3755–3763, 2002.
[38] K. Campbell, H. Diao, J. Ji, and L. Soong, “DNA immuniza-
tion with the gene encoding P4 nuclease of Leishmania ama-
zonensis protects mice against cutaneous leishmaniasis,” In-
fection and Immunity, vol. 71, no. 11, pp. 6270–6278, 2003.
[39] E. Dumonteil, F. Andrade-Narvarez, J. Escobedo-Ortegon, et
al., “Comparative study of DNA vaccines encoding various
antigens against Leishmania mexicana,” Developments in Bio-
logicals, vol. 104, pp. 135–141, 2000.
[40] I. Aguilar-Be, R. da Silva Zardo, E. Paraguai de Souza, et al.,
“Cross-protective eﬃcacyofaprophylactic Leishmaniadono-
vani DNA vaccine against visceral and cutaneous murine
leishmaniasis,” Infection and Immunity,v o l .7 3 ,n o .2 ,p p .
812–819, 2005.
[41] M. Rosado-Vallado, M. Mut-Martin, M. R. Garc´ ıa-Miss, and
E. Dumonteil, “Aluminium phosphate potentiates the eﬃ-
cacy of DNA vaccines against Leishmania mexicana,” Vaccine,
vol. 23, no. 46-47, pp. 5372–5379, 2005.
[42] S. Rafati, F. Zahedifard, and F. Nazgouee, “Prime-boost vac-
cination using cysteine proteinases type I and II of Leishma-
nia infantum confers protective immunity in murine visceral
leishmaniasis,” Vaccine, vol. 24, no. 12, pp. 2169–2175, 2006.
[43] B.Sukumaran,P.Tewary,S.Saxena,andR.Madhubala,“Vac-
cination with DNA encoding ORFF antigen confers protec-
tive immunity in mice infected with Leishmania donovani,”
Vaccine, vol. 21, no. 11-12, pp. 1292–1299, 2003.
[44] A.Sj¨ olander,T.M.Baldwin,J.M.Curtis,K.L.Bengtsson,and
E. Handman, “Vaccination with recombinant Parasite Sur-
face Antigen 2 from Leishmania major induces a Th1 type
of immune response but does not protect against infection,”
Vaccine, vol. 16, no. 20, pp. 2077–2084, 1998.
[45] S. M´ endez, S. Gurunathan, S. Kamhawi, et al., “The po-
tency and durability of DNA- and protein-based vaccines
againstLeishmaniamajor evaluatedusinglow-dose,intrader-
mal challenge,” The Journal of Immunology, vol. 166, no. 8,
pp. 5122–5128, 2001.
[46] M. A. Barry, W. C. Lai, and S. A. Johnston, “Protection
against mycoplasma infection using expression-library im-
munization,” Nature, vol. 377, no. 6550, pp. 632–635, 1995.
[ 4 7 ]D .P i e d r a ﬁ t a ,D .X u ,D .H u n t e r ,R .A .H a r r i s o n ,a n dF .Y .
Liew, “Protective immune responses induced by vaccination
with an expression genomic library of Leishmania major,”
The Journal of Immunology, vol. 163, no. 3, pp. 1467–1472,
1999.
[48] P. C. Melby, G. B. Ogden, H. A. Flores, et al., “Identiﬁcation
of vaccine candidates for experimental visceral leishmania-
sis by immunization with sequential fractions of a cDNA ex-
pression library,” Infection and Immunity, vol. 68, no. 10, pp.
5595–5602, 2000.
[49] A. C. Ivens, C. S. Peacock, E. A. Worthey, et al., “The genome
of the kinetoplastid parasite, Leishmania major,” Science,
vol. 309, no. 5733, pp. 436–442, 2005.
[50] C. B. Stober, “From genomes to vaccines for leishmaniasis,”
Methods in Molecular Biology, vol. 270, pp. 423–438, 2004.
[ 5 1 ]C .B .S t o b e r ,U .G .L a n g e ,M .T .M .R o b e r t s ,e ta l . ,“ F r o m
genome to vaccines for leishmaniasis: screening 100 novel
vaccine candidates against murine Leishmania major infec-
tion,” Vaccine, vol. 24, no. 14, pp. 2602–2616, 2006.
[52] N.G.Saravia,M.H.Hazb´ on,Y.Osorio,etal.,“Protectiveim-
munogenicityoftheparaﬂagellarrodprotein2ofLeishmania
mexicana,” Vaccine, vol. 23, no. 8, pp. 984–995, 2005.
[ 5 3 ]R .B a s u ,S .B h a u m i k ,J .M .B a s u ,K .N a s k a r ,T .D e ,a n d
S. Roy, “Kinetoplastid membrane protein-11 DNA vacci-
nation induces complete protection against both pentava-
lent antimonial-sensitive and -resistant strains of Leishmania
donovani that correlates with inducible nitric oxide synthase
activity and IL-4 generation: evidence for mixed Th1- and
Th2-like responses in visceral leishmaniasis,” The Journal of
Immunology, vol. 174, no. 11, pp. 7160–7171, 2005.
[54] K. Fragaki, I. Suﬃa, B. Ferrua, D. Rousseau, Y. Le Fichoux,
and J. Kubar, “Immunisation with DNA encoding Leishma-
nia infantum protein papLe22 decreases the frequency of
parasitemic episodes in infected hamsters,” Vaccine, vol. 19,
no. 13-14, pp. 1701–1709, 2001.
[ 5 5 ] M .J .R a m i r o ,J .J .Z´ arate, T. Hanke, et al., “Protection in dogs
against visceral leishmaniasis caused by Leishmania infan-
tumisachievedbyimmunizationwithaheterologousprime-
boost regime using DNA and vaccinia recombinant vectors
expressingLACK,”Vaccine,vol.21,no.19-20,pp.2474–2484,
2003.10 Journal of Biomedicine and Biotechnology
[56] O. A. Saldarriaga, B. L. Travi, W. Park, L. E. Perez, and P.
C. Melby, “Immunogenicity of a multicomponent DNA vac-
cine against visceral leishmaniasis in dogs,” Vaccine, vol. 24,
no. 11, pp. 1928–1940, 2006.
[57] S. Rafati, A. Nakhaee, T. Taheri, et al., “Protective vaccina-
tion against experimental canine visceral leishmaniasis us-
ing a combination of DNA and protein immunization with
cysteine proteinases type I and II of L. infantum,” Vaccine,
vol. 23, no. 28, pp. 3716–3725, 2005.
[58] B.Autran,G.Carcelain,B.Combadiere,andP.Debre,“Ther-
apeutic vaccines for chronic infections,” Science, vol. 305,
no. 5681, pp. 205–208, 2004.
[59] E. Handman, A. H. Noormohammadi, J. M. Curtis, T. Bald-
win, and A. Sj¨ olander, “Therapy of murine cutaneous leish-
maniasis by DNA vaccination,” Vaccine, vol. 18, no. 26, pp.
3011–3017, 2000.
[60] R. Gamboa-Le´ o n ,E .P a r a g u a id eS o u z a ,G .P .B o r j a - C a b r e r a ,
et al., “Immunotherapy against visceral leishmaniasis with
the nucleoside hydrolase-DNA vaccine of Leishmania dono-
vani,” Vaccine, vol. 24, no. 22, pp. 4863–4873, 2006.
[61] J. R. Espinoza, A. C. Skinner, C. R. Davies, et al., “Extensive
polymorphism at the Gp63 locus in ﬁeld isolates of Leish-
mania peruviana,” Molecular and Biochemical Parasitology,
vol. 72, no. 1-2, pp. 203–213, 1995.
[62] S. Guerbouj, K. Victoir, I. Guizani, et al., “Gp63 gene poly-
morphism and population structure of Leishmania donovani
complex: inﬂuence of the host selection pressure?” Parasitol-
ogy, vol. 122, no. 1, pp. 25–35, 2001.
[63] F. Alvarez-Valin, J. F. Tort, and G. Bernardi, “Nonrandom
spatial distribution of synonymous substitutions in the GP63
gene from Leishmania,” Genetics, vol. 155, no. 4, pp. 1683–
1692, 2000.
[64] S. Guerbouj, I. Guizani, K. Victoir, D. Le Ray, and J.-
C. Dujardin, “Parasite candidate vaccines: a warning from
polymorphic Leishmania populations,” Parasitology Today,
vol. 16, no. 6, pp. 265–266, 2000.
[65] D. A. Fitzpatrick, C. J. Creevey, and J. O. McInerney, “Evi-
dence of positive Darwinian selection in putative meningo-
coccal vaccine antigens,” Journal of Molecular Evolution,
vol. 61, no. 1, pp. 90–98, 2005.
[66] C. Kumkhaek, K. Phra-Ek, L. R´ enia, et al., “Are extensive T
cell epitope polymorphisms in the Plasmodium falciparum
circumsporozoite antigen, a leading sporozoite vaccine can-
didate, selected by immune pressure?” The Journal of Im-
munology, vol. 175, no. 6, pp. 3935–3939, 2005.
[67] E. F. Pinto, R. O. Pinheiro, A. Rayol, V. Larraga, and B. Rossi-
Bergmann, “Intranasal vaccination against cutaneous leish-
maniasis with a particulated leishmanial antigen or DNA en-
coding LACK,” Infection and Immunity,v o l .7 2 ,n o .8 ,p p .
4521–4527, 2004.
[68] Y. Belkaid, S. Kamhawi, G. Modi, et al., “Development of a
natural model of cutaneous leishmaniasis: powerful eﬀects
of vector saliva and saliva preexposure on the long-term out-
come of Leishmania major infection in the mouse ear der-
mis,” The Journal of Experimental Medicine, vol. 188, no. 10,
pp. 1941–1953, 1998.
[69] M. L. Mbow, J. A. Bleyenberg, L. R. Hall, and R. G. Titus,
“Phlebotomus papatasi sand ﬂy salivary gland lysate down-
regulates a Th1, but up-regulates a Th2, response in mice in-
fected with Leishmania major,” The Journal of Immunology,
vol. 161, no. 10, pp. 5571–5577, 1998.
[70] S. Kamhawi, Y. Belkaid, G. Modi, E. Rowton, and D. Sacks,
“Protection against cutaneous leishmaniasis resulting from
bites of uninfected sand ﬂies,” Science, vol. 290, no. 5495, pp.
1351–1354, 2000.
[71] R.V.Morris,C.B.Shoemaker,J.R.David,G.C.Lanzaro,and
R. G. Titus, “Sandﬂy maxadilan exacerbates infection with
Leishmania major and vaccinating against it protects against
L. major infection,” The Journal of Immunology, vol. 167,
no. 9, pp. 5226–5230, 2001.
[72] J. G. Valenzuela, Y. Belkaid, M. K. Garﬁeld, et al., “Toward
a deﬁned anti-Leishmania vaccine targeting vector antigens:
characterization of a protective salivary protein,” The Journal
of Experimental Medicine, vol. 194, no. 3, pp. 331–342, 2001.
[73] J. M. Anderson, F. Oliveira, S. Kamhawi, et al., “Comparative
salivary gland transcriptomics of sandﬂy vectors of visceral
leishmaniasis,” BMC Genomics, vol. 7, p. 52, 2006.
[74] J. G. Valenzuela, M. Garﬁeld, E. D. Rowton, and V. M. Pham,
“Identiﬁcation of the most abundant secreted proteins from
the salivary glands of the sand ﬂy Lutzomyia longipalpis,v e c -
tor of Leishmania chagasi,” The Journal of Experimental Biol-
ogy, vol. 207, no. 21, pp. 3717–3729, 2004.
[75] D.-E. A. Elnaiem, C. Meneses, M. Slotman, and G. C. Lan-
zaro, “Genetic variation in the sand ﬂy salivary protein, SP-
15, a potential vaccine candidate against Leishmania major,”
Insect Molecular Biology, vol. 14, no. 2, pp. 145–150, 2005.
[76] R. S. Milleron, J.-P. Mutebi, S. Valle, et al., “Antigenic diver-
sity in maxadilan, a salivary protein from the sand ﬂy vec-
tor of American visceral leishmaniasis,” American Journal of
Tropical Medicine and Hygiene, vol. 70, no. 3, pp. 286–293,
2004.
[77] E. M. Saraiva, A. de Figueiredo Barbosa, F. N. Santos, et
al., “The FML-vaccine (Leishmune
) against canine vis-
ceral leishmaniasis: a transmission blocking vaccine,” Vac-
cine, vol. 24, no. 13, pp. 2423–2431, 2006.
[78] N. Giron´ e s ,H .C u e r v o ,a n dM .F r e s n o ,“ Trypanosoma cruzi-
induced molecular mimicry and Chagas’ disease,” Current
Topics in Microbiology and Immunology, vol. 296, pp. 89–123,
2005.
[79] R.L.Tarleton,“ParasitepersistenceintheaetiologyofChagas
disease,” International Journal for Parasitology, vol. 31, no. 5-
6, pp. 549–553, 2001.
[80] V. Bhatia and N. Garg, “Current status and future prospects
for a vaccine against American trypanosomiasis,” Expert Re-
view of Vaccines, vol. 4, no. 6, pp. 867–880, 2005.
[81] F. Kierszenbaum, “Where do we stand on the autoimmunity
hypothesis of Chagas disease?” Trends in Parasitology, vol. 21,
no. 11, pp. 513–516, 2005.
[82] D. F. Hoft, A. R. Schnapp, C. S. Eickhoﬀ, and S. T. Roodman,
“Involvement of CD4+ Th1 cells in systemic immunity pro-
tective against primary and secondary challenges with Try-
panosoma cruzi,” Infection and Immunity,v o l .6 8 ,n o .1 ,p p .
197–204, 2000.
[83] D.MartinandR.Tarleton,“Generation,speciﬁcity,andfunc-
tion of CD8+ Tc e l l si nTrypanosoma cruzi infection,” Im-
munological Reviews, vol. 201, no. 1, pp. 304–317, 2004.
[84] M. M. Rodrigues, M. Ribeir˜ a o ,V .P e r e i r a - C h i o c c o l a ,L .R e -
nia, and F. Costa, “Predominance of CD4 Th1 and CD8 Tc1
cells revealed by characterization of the cellular immune re-
sponse generated by immunization with a DNA vaccine con-
taining a Trypanosoma cruzi gene,” Infection and Immunity,
vol. 67, no. 8, pp. 3855–3863, 1999.
[85] M. M. Rodrigues, S. B. Boscardin, J. R. Vasconcelos, M. I.
Hiyane,G.Salay, andI.S.Soares,“ImportanceofCD8Tcell-
mediated immune response during intracellular parasitic in-
fections and its implications for the development of eﬀectiveEric Dumonteil 11
vaccines,” Anais da Academia Brasileira de Ciˆ encias, vol. 75,
no. 4, pp. 443–468, 2003.
[86] F. Costa, G. Franchin, V. L. Pereira-Chioccola, M. Ribeir˜ ao,
S. Schenkman, and M. M. Rodrigues, “Immunization with a
plasmid DNA containing the gene of trans-sialidase reduces
Trypanosoma cruzi infection in mice,” Vaccine, vol. 16, no. 8,
pp. 768–774, 1998.
[87] N. Garg and R. L. Tarleton, “Genetic immunization elicits
antigen-speciﬁc protective immune responses and decreases
diseaseseverityinTrypanosomacruziinfection,”Infectionand
Immunity, vol. 70, no. 10, pp. 5547–5555, 2002.
[88] B.Wizel,M.Nunes,andR.L.Tarleton,“IdentiﬁcationofTry-
panosoma cruzi trans-sialidase family members as targets of
protective CD8+ TC1 responses,” The Journal of Immunology,
vol. 159, no. 12, pp. 6120–6130, 1997.
[89] F. Costa, V. L. Pereira-Chioccola, M. Ribeir˜ a o ,S .S c h e n k m a n ,
a n dM .M .R o d r i g u e s ,“ Trans-sialidase delivered as a naked
DNA vaccine elicits an immunological response similar to
a Trypanosoma cruzi infection,” Brazilian Journal of Medical
and Biological Research, vol. 32, no. 2, pp. 235–239, 1999.
[90] V. L. Pereira-Chioccola, F. Costa, M. Ribeir˜ ao, et al., “Com-
parison of antibody and protective immune responses
against Trypanosoma cruzi infection elicited by immuniza-
tion with a parasite antigen delivered as naked DNA or re-
combinant protein,” Parasite Immunology,v o l .2 1 ,n o .2 ,p p .
103–110, 1999.
[91] B. Wizel, N. Garg, and R. L. Tarleton, “Vaccination with try-
pomastigote surface antigen 1-encoding plasmid DNA con-
fers protection against lethal Trypanosoma cruzi infection,”
Infection and Immunity, vol. 66, no. 11, pp. 5073–5081, 1998.
[92] G.A.Garc´ ıa,M.R.Arnaiz,S.A.Laucella,etal.,“Immunolog-
ical and pathological responses in BALB/c mice induced by
genetic administration of Tc13 Tul antigen of Trypanosoma
cruzi,” Parasitology, vol. 132, no. 6, pp. 855–866, 2006.
[93] S. B. Boscardin, S. S. Kinoshita, A. E. Fujimura, and M. M.
Rodrigues,“ImmunizationwithcDNAexpressedbyamastig-
otes of Trypanosoma cruzi elicits protective immune re-
sponse against experimental infection,” Infection and Immu-
nity, vol. 71, no. 5, pp. 2744–2757, 2003.
[94] M. Katae, Y. Miyahira, K. Takeda, et al., “Coadministration
of an interleukin-12 gene and a Trypanosoma cruzi gene
improves vaccine eﬃcacy,” Infection and Immunity, vol. 70,
no. 9, pp. 4833–4840, 2002.
[95] Y.Miyahira,M.Katae,K.Takeda,etal.,“Activationofnatural
killer T cells by α-galactosylceramide impairs DNA vaccine-
inducedprotectiveimmunityagainstTrypanosomacruzi,” In-
fection and Immunity, vol. 71, no. 3, pp. 1234–1241, 2003.
[96] B. H. Fralish and R. L. Tarleton, “Genetic immunization with
LYT1 or a pool of trans-sialidase genes protects mice from
lethal Trypanosoma cruzi infection,” Vaccine, vol. 21, no. 21-
22, pp. 3070–3080, 2003.
[97] J. R. Vasconcelos, M. I. Hiyane, C. R. F. Marinho, et al.,
“Protective immunity against Trypanosoma cruzi infection
in a highly susceptible mouse strain after vaccination with
genes encoding the amastigote surface protein-2 and trans-
sialidase,” Human Gene Therapy, vol. 15, no. 9, pp. 878–886,
2004.
[98] P. Sepulveda, M. Hontebeyrie, P. Liegeard, A. Mascilli, and
K. A. Norris, “DNA-based immunization with Trypanosoma
cruzicomplementregulatoryproteinelicitscomplementlytic
antibodies and confers protection against Trypanosoma cruzi
infection,” Infection and Immunity, vol. 68, no. 9, pp. 4986–
4991, 2000.
[99] A. R. Schnapp, C. S. Eickhoﬀ,J .S c h a r f s t e i n ,a n dD .F .H o f t ,
“Induction of B- and T-cell responses to cruzipain in the
murine model of Trypanosoma cruzi infection,” Microbes and
Infection, vol. 4, no. 8, pp. 805–813, 2002.
[100] L. Planelles, M. C. Thomas, C. Alonso, and M. C. L´ opez,
“DNA immunization with Trypanosoma cruzi HSP70 fused
to the KMP11 protein elicits a cytotoxic and humoral im-
mune response against the antigen and leads to protection,”
Infection and Immunity, vol. 69, no. 10, pp. 6558–6563, 2001.
[101] F. Tzelepis, B. C. G. de Alencar, M. L. O. Penido, R. T. Gazz-
inelli, P. M. Persechini, and M. M. Rodrigues, “Distinct ki-
netics of eﬀector CD8+ cytotoxic T cells after infection with
Trypanosomacruziinna¨ ıveorvaccinatedmice,”Infection and
Immunity, vol. 74, no. 4, pp. 2477–2481, 2006.
[102] A. E. Fujimura, S. S. Kinoshita, V. L. Pereira-Chioccola,
and M. M. Rodrigues, “DNA sequences encoding CD4
+ and
CD8
+ T-cell epitopes are important for eﬃcient protective
immunity induced by DNA vaccination with a Trypanosoma
cruzi gene,” Infection and Immunity, vol. 69, no. 9, pp. 5477–
5486, 2001.
[103] J. R. Vasconcelos, S. B. Boscardin, M. I. Hiyane, S. S. Ki-
noshita, A. E. Fujimura, and M. M. Rodrigues, “A DNA-
priming protein-boosting regimen signiﬁcantly improves
type 1 immune response but not protective immunity to
Trypanosoma cruzi infection in a highly susceptible mouse
strain,” Immunology and Cell Biology, vol. 81, no. 2, pp. 121–
129, 2003.
[104] E. Dumonteil, J. Escobedo-Ortegon, N. Reyes-Rodriguez, A.
Arjona-Torres, and M. J. Ramirez-Sierra, “Immunotherapy
of Trypanosoma cruzi infection with DNA vaccines in mice,”
Infection and Immunity, vol. 72, no. 1, pp. 46–53, 2004.
[105] G. Sanchez-Burgos, G. Mezquita-Vega, J. Escobedo-Ortegon,
et al., “Comparative eﬃcacy of DNA vaccines encod-
ing various Trypanosoma cruzi antigens,” FEMS Immu-
nology and Medical Microbiology,(Online Early Articles)
Doi:10.1111/j.1574-695X.2007.00251.X, 2007.
[106] H. Zapata-Estrella, C. Hummel-Newell, G. Sanchez-Burgos,
et al., “Control of Trypanosoma cruzi infection and changes
in T-cell populations induced by a therapeutic DNA vaccine
in mice,” Immunology Letters, vol. 103, no. 2, pp. 186–191,
2006.
[107] E.Alberti,A.Acosta,M.E.Sarmiento,etal.,“Speciﬁccellular
and humoral immune response in Balb/c mice immunised
with an expression genomic library of Trypanosoma cruzi,”
Vaccine, vol. 16, no. 6, pp. 608–612, 1998.
[108] V. Bhatia, M. Sinha, B. Luxon, and N. Garg, “Utility of the
Trypanosoma cruzi sequence database for identiﬁcation of
potential vaccine candidates by in silico and in vitro screen-
ing,” Infection and Immunity, vol. 72, no. 11, pp. 6245–6254,
2004.
[109] S. Manoj, L. A. Babiuk, and S. van Drunen Littel-van den
Hurk, “Approaches to enhance the eﬃcacy of DNA vaccines,”
Critical Reviews in Clinical Laboratory Sciences, vol. 41, no. 1,
pp. 1–39, 2004.
[110] M. Moutaftsi, B. Peters, V. Pasquetto, et al., “A consensus epi-
tope prediction approach identiﬁes the breadth of murine
TCD8+-cell responses to vaccinia virus,” Nature Biotechnology,
vol. 24, no. 7, pp. 817–819, 2006.